Full content is available to subscribers

Amyloid and Alzheimer Disease

Extract

A protein encoded by a variant of the APOE gene that is implicated in many cases of late-onset sporadic Alzheimer disease slows clearance of amyloid-β, contributing to amyloid-β build-up in the brain (Castellano JM et al. Sci Transl Med. 2011;3[89]:89ra57).

In cognitively normal individuals who are younger than age 70 years, those with APOE ε4 protein had significantly more amyloid-β protein in the brain than individuals with either APOE ε2 and APOE ε3, the proteins encoded by other variants of the APOE gene.

Purchase Options

Figures

Tables

References

Letters

The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with
the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.

This feature is provided as a courtesy. By using it you agree that that you are requesting the material solely for personal, non-commercial use, and that it is subject to the AMA's Terms of Use. The information provided in order to email this article will not be shared, sold, traded, exchanged, or rented. Please refer to The JAMA Network's Privacy Policy for additional information.

Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.